Literature DB >> 8388497

Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.

I Bahner1, C Zhou, X J Yu, Q L Hao, J C Guatelli, D B Kohn.   

Abstract

trans-Dominant inhibitory mutant versions of the human immunodeficiency virus type 1 (HIV-1) regulatory genes tat and rev have previously been described. We have constructed a series of retroviral vectors to transduce these genes and compare their inhibitory activities. The inhibitory activities were measured with transient transfection assays by using a reporter which expresses an HIV-1 gag-Escherichia coli lacZ fusion protein with strict dependence on coexpression of both tat and rev. Additionally, the vectors were packaged as amphotropic virions and used to stably transduce human CEM T lymphocytes. The transduced CEM cells were challenged with HIV-1, and the effects of the mutant HIV-1 genes were determined by measuring the levels of HIV-1 p24gag produced. A tat gene substituted at amino acid 41 (tatk41a) retained partial trans-activating activity and lacked inhibitory activity. A tat gene with a premature stop codon at amino acid 54 (tat54ter) showed moderate trans-dominant inhibition of the reporter plasmid but failed to significantly inhibit HIV-1 replication. The M10 rev mutant, with a 2-amino-acid substitution, showed strong trans-dominant inhibitory activity both in the reporter plasmid and in the HIV-1 infection assay. The greatest inhibition of HIV-1 growth was seen when M10 was expressed under the transcriptional control of a human cytomegalovirus promoter; slightly less inhibition was achieved when expression of M10 was controlled by the Moloney murine leukemia virus long terminal repeat, and minimal inhibition was seen when the HIV-1 long terminal repeat controlled the M10 gene. These results demonstrate the potential utility of retroviral vectors expressing trans-dominant inhibitory mutant HIV-1 genes for gene therapy approaches to AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388497      PMCID: PMC237659     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Authors:  B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

2.  Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain?

Authors:  L S Tiley; P H Brown; B R Cullen
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

3.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

4.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

5.  A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.

Authors:  L Pearson; J Garcia; F Wu; N Modesti; J Nelson; R Gaynor
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein.

Authors:  B K Felber; C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

7.  Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency.

Authors:  R J Pomerantz; D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

8.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

9.  Gene therapy. Intracellular immunization.

Authors:  D Baltimore
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

10.  Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA.

Authors:  A Rhodes; W James
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

View more
  31 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Nucleocytoplasmic shuttling of HIV-1 integrase is controlled by the viral Rev protein.

Authors:  Aviad Levin; Zvi Hayouka; Assaf Friedler; Abraham Loyter
Journal:  Nucleus       Date:  2010-01-14       Impact factor: 4.197

Review 3.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation.

Authors:  F McPhee; A C Good; I D Kuntz; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle.

Authors:  Sook-Kyung Lee; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

7.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

8.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.

Authors:  R K Akkina; R M Walton; M L Chen; Q X Li; V Planelles; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  The activation region of the Tat protein of human immunodeficiency virus type-1 functions in yeast.

Authors:  T Subramanian; C D'Sa-Eipper; B Elangovan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

10.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.